

**CURRICULUM VITAE – NIKHIL PATKAR**

**Name** Nikhil Vijay Patkar  
**Current Address** Hematopathology Laboratory, Center for Cancer Epidemiology, ACTREC, Tata Memorial Centre, Mumbai  
**Phone** +912227405000 Ext: 5789  
**Email** [nvpatkar@gmail.com](mailto:nvpatkar@gmail.com), [npatkar@actrec.gov.in](mailto:npatkar@actrec.gov.in)

**Degrees/Diplomates**

Date	Degree	Place obtained
1996 - 2001	MBBS	Grant Medical College, University of Mumbai
2003 – 2006	MD	Armed Forces Medical College, University of Pune
2006	DNB	National Board of Examinations, New Delhi

**Honors and Awards**

1. **Wellcome Trust-DBT India Alliance Senior Fellowship (2021-Current).** This competitive fellowship scheme is co-funded by the Wellcome Trust, UK and the Department of Science and Biotechnology, Govt of India for established researchers.
2. **Wellcome Trust-DBT India Alliance Intermediate Fellowship (2015-2021).** This competitive fellowship scheme is co-funded by the Wellcome Trust, UK and the Department of Science and Biotechnology, Govt of India for intermediate career researchers.
3. The **Charles Morehead Prize** in the year 2000 “for having passed the final MBBS examination with the highest number of marks in Clinical Medicine including Paediatrics in the University of Bombay” – Awarded by the University of Mumbai 2001
4. The **Dr. J.K. Mehta** prize in the year 2000 “for having passed the final MBBS examination with the highest number of marks in Clinical Medicine including Paediatrics in the University of Bombay”- Awarded by the University of Mumbai 2001

**Research Funding:**

1. Centre for Advanced Research on Innovation in Diagnosis, Prognostication, and Monitoring of Acute Myeloid Leukemia. Funding: Rs 14.50 Crores (~USD 1.7 Million) **Indian Council of Medical Research**, Govt of India
2. Rapid and Affordable Diagnostics for stratifying Childhood Acute Lymphoblastic leukemia (RADICAL). Funding: Rs 7.70 Crores (~USD 916,000) **Indian Council of Medical Research**, Govt of India
3. Acute myeloid leukemia and the clonal dynamics of relapse. Funding: Rs 4.7crores (~ USD 650,000) **Wellcome Trust UK and Department of Science and Biotechnology**, Govt of India
4. Comprehensive Molecular Characterisation of Pediatric Acute Leukemia with Whole Transcriptome Sequencing (WTS). Funding: Rs2.90Cr (~USD353,000) by **Illumina Inc – Medical Research Division, USA**
5. Applicability of Measurable Residual Disease Testing in Acute Lymphoblastic Leukemia by Next Generation Sequencing. Funding: USD 200,000 by **ThermoFisher Inc, Oncomine Global Grant**.

6. Acute myeloid leukemia and the dynamics of relapse. Funding: Rs 3.67crores (~ USD 550,000) **Wellcome Trust UK and Department of Science and Biotechnology**, Govt of India (IECIII: Project No 163) – 2015-2021
7. Unravelling the genomic context of relapse initiating cells in adult acute myeloid leukemia: Rs 1.45 Crores (~USD 185,300) by **Indian Council of Medical Research**, Govt of India – 2020-2024
8. Metagenomics (mNGS) for the rapid identification of pathogenic organisms causing sepsis in adult patients of acute leukaemia (AL) including those undergoing bone marrow transplantation (BMT). Funding: Rs1.69Cr (~USD 200,000) by **Lady Tata Memorial Trust** – 2021-2024

#### **Professional Appointments (Current)**

1. Clinician Scientist and Professor, Hematopathology, **Tata Memorial Centre**, Mumbai (7<sup>th</sup> Nov 2012 – current)

#### **Professional Appointments (Past)**

1. Visiting Faculty, Department of Computational Biology, Gavin Ha Lab, **Fred Hutchinson Cancer Research Centre**, Seattle, USA (1<sup>st</sup> Apr 2025 to 31<sup>th</sup> August 2025)
2. Affiliate Faculty – Department of Laboratory Medicine, **University of Washington**, Seattle, WA, USA – 1<sup>st</sup> October 2019 – 30<sup>th</sup> June 2021
3. Visiting Scholar, Department of Genome Sciences, Shendure Lab, **University of Washington**, Seattle, USA (1<sup>st</sup> Sep 2016 to 31<sup>th</sup> Aug 2017)
4. Visiting Scholar, Department of Laboratory Medicine, **University of Washington & Seattle Cancer Care Alliance**, Seattle, USA (1<sup>st</sup> Sep 2016 to 31<sup>th</sup> Aug 2017)
5. Post Doctoral Fellow, **Hematologics Inc**, Seattle, WA (1<sup>st</sup> October 2011 to 20<sup>th</sup> Oct 2012)
6. Fellow in Molecular Haematology, Department of Clinical Haematology, **Christian Medical College**, Vellore (1<sup>st</sup> August 2009 to July 2011)
7. Fellow, Department of Clinical Haematology, **Christian Medical College**, Vellore (March 25 2009- 31<sup>st</sup> July 2009)
8. Fellow, Department of Immunohematology and Transfusion Medicine, **Christian Medical College**, Vellore (March 20 2008- March 24 2009)
9. Fellow (Senior Resident), Hematopathology laboratory, Department of Pathology, **Tata Memorial Hospital** (March 01 2007-Feb 28 2008)

#### **International Collaboration**

- A. Invited Member: **Classification Advancement Meeting (CAM) for hematopoietic neoplasms for the 6th edition of the WHO Classification of Myeloid and Lymphoid Neoplasms**. March 2026. This is a joint effort between former members of the World Health Organization (WHO) 5th edition Classification and the International Consensus Classification (ICC) of hematopoietic neoplasms. Part of the Acute Leukemia and Myeloid Malignancies Taskforce Groups.**Part of the 10 member core committee on Acute Myeloid Leukemia**
- B. Invited to co-author the **5th edition of the WHO Classification of Tumours - Haematolymphoid Tumours** by the International Agency for Research on Cancer, Lyon, France. **Part of the Myeloid Subcommittee for Myelodysplastic Syndromes and Acute Myeloid Leukemia.**

The Classification is published in *Leukemia* in 2022

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, **Patkar N**, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. **The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms** Leukemia. 2022 Jul;36(7):1703-1719.

Author on the following chapters:

- 2.2.3.10 Myelodysplastic neoplasm, hypoplastic
- 2.3.1.9 Acute myeloid leukaemia with *NUP98* rearrangement
- 2.5.2.3 Mixed-phenotype acute leukaemia with *KMT2A* rearrangement
- 2.2.3.2 Myelodysplastic neoplasm with low blasts and isolated 5q deletion
- 2.2.3.3 Myelodysplastic neoplasm with low blasts and *SF3B1* mutation
- 2.2.3.5 Myelodysplastic neoplasm with increased blasts
- 2.3.1.3 Acute myeloid leukaemia with *RUNX1-RUNX1T1* fusion
- 2.3.1.5 Acute myeloid leukaemia with *KMT2A* rearrangement
- 2.3.1.6 Acute myeloid leukaemia with *DEK-NUP214* fusion
- 2.3.1.10 Acute myeloid leukaemia with other defined driver gene alterations
- 2.3.1.11 Acute myeloid leukemia with myelodysplasia-related cytogenetics
- 2.4.1.2 Myeloid neoplasm post cytotoxic therapy

- C. Invited to participate by the **Association for Molecular Pathology** as part of the working group on **Recommendations for Molecular MRD Monitoring in Acute Myeloid Leukemia (Joint Guidelines by College of American Pathologists, Association for Molecular Pathology and American Society of Hematology)**
- D. Appointed as a member of the International Affairs Committee, **Association for Molecular Pathology, USA**  
<https://www.amp.org/about/committees/international-affairs-committee/>

#### **National Committees:**

1. Working Group Member, National Genomics Data Grid (NGDG), Department of Biotechnology, Govt of India
2. Committee Member: National Mission Program on Cell & Gene Therapy (NMCGT), Department of Biotechnology, Govt of India
3. Member, Technical Expert Committee, Cancer Research Program, Department of Biotechnology, Govt of India

#### **Patents:**

1. Method for Sequencing Pre-Selected Genomic Regions by Asymmetrically Looped Strand-Biased Oligonucleotides and Hemi-Nested PCR.
2. A method and a kit for generating nucleic acid for target capture. (PCT Patent Filed: PCT/IN2025/051311)

#### **Editorial Board Responsibilities:**

1. Journal of Clinical Pathology, Editorial Board Member
2. Molecular Diagnosis & Therapy, Editorial Board Member

**Institutional Committees:**

1. Member, Tata Memorial Centre, Research and Development Cell
2. Member, ACTREC, TMC - Intellectual Property Rights (IPR) Cell
3. Member, Artificial Intelligence-Machine Learning & Data Science Working Group, ACTREC
4. Member, Research Mentors Group – Tata Memorial Centre

**Educational Outreach:**

1. ***Observers and Trainee Mentorship:*** The hematopathology and molecular laboratory annually hosts several observers (clinical and basic research) from all over India and neighbouring countries. These observers under my guidance are taught basic aspects of hematopathology, molecular pathology and laboratory techniques pertinent to clinical diagnostics.
2. ***Meetings & Workshops Organized in ACTREC, Tata Memorial Centre:*** I have organized several workshops and CME courses in ACTREC. These include Evidence-Based Meetings in 2015 and 2018 for Molecular Hematopathology and Workshops on Bioinformatics. We also hold annual recurring workshops on basic and advanced molecular pathology.
  - a. Organizing Secretary “Basic Workshop on Molecular Hematopathology” 14-16 Sep 2023, ACTREC, Tata Memorial Centre
  - b. Organizing Secretary “Genomics Workshop in Molecular Hematopathology” 24-28 Sep 2024, ACTREC, Tata Memorial Centre
3. ***Meetings Coordinated with Scientific Organizations:*** At the national level, I have participated and, at times, conducted workshops and CMEs with national bodies like Haematocon (National Haematology Society Annual Congress), Molecular Pathology Association of India, and State Pathology Societies.

**Societal Outreach and Contribution to COVID-19:**

1. Community Testing: Contributed to COVID-19 testing for ACTREC, as well as volunteered to test thousands of community samples during the pandemic. We have sequenced close to 1000 COVID-19 genomes during the first and second waves of the pandemic.  
(<https://pubmed.ncbi.nlm.nih.gov/35685574/>)
2. I was a member of the ACTREC COVID-19 Response Team and was responsible for establishing molecular diagnostics and related coordination during the COVID-19 pandemic. I also coordinated data with authorities from local municipal, state, and national bodies such as Navi Mumbai Municipal Corporation, Maharashtra COVID-19 Cell, Department of Biotechnology.

**National Guidelines:**

Indian Council of Medical Research Subcommittee on Acute Lymphoblastic Leukemia: Consensus Document on Treatment of Acute Lymphoblastic Leukemia (Role as Molecular Pathologist): Ongoing

Indian Council of Medical Research: Standard Operating Procedures for Immunophenotyping of Hematolymphoid Neoplasms ([http://icmr.nic.in/About\\_Us/Guidelines.html](http://icmr.nic.in/About_Us/Guidelines.html))

**Research & Selected Publications:**

Complete list of 90+ papers can be seen here:

<https://pubmed.ncbi.nlm.nih.gov/?term=Patkar+Nikhil&sort=date>

H-index: 22

<https://scholar.google.co.in/citations?user=BE4IKmQAAAAJ&hl=en>

1. **Measurable Residual Disease Detection for Acute Myeloid Leukemia:** Our laboratory has led pioneering clinical work comparing multiparameter flow cytometry and error corrected panel-based next generation sequencing for detection of MRD in acute myeloid leukemia.
  - a. **Nikhil Patkar\***, Chinmayee Kakirde, Anam Fatima Shaikh et al. Clinical Impact of Panel Based Error Corrected Next Generation Sequencing versus Flow Cytometry to Detect Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) *Leukemia* 2021 May;35(5):1392-1404 (**Impact Factor: 12.88**)
  - b. **Nikhil Patkar\***, Rohan Kodgule , Chinmayee Kakirde , et al. Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia. *Oncotarget*. 2018 Nov 27;9(93):36613-36624 (**Impact Factor: 5.168**)
  - c. **Nikhil Patkar\***, Chinmayee Kakirde, Prasanna Bhanshe, et al. Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia – Real World Context. *Front Oncol*. 2019 Jun 13;9:450 (**Impact Factor: 6.5**)
2. **Development of Next Generation Sequencing (and other molecular) Methods for Blood Cancers:** The focus of my research is the development of affordable yet cutting edge (largely next generation sequencing based) molecular methods for diagnosis, prognostication and monitoring of blood cancers. Although the below work is specifically on developing new methods, every NGS assay in our lab is a laboratory-developed assay.
  - a. **Nikhil Patkar\***, Prasanna Bhanshe, Sweta Rajpal, et al. NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies. *Blood Cancer Journal* 2020 May 5;10(5):50 (**Impact Factor: 12.8**)
  - b. **Nikhil Patkar**, Swapnali Joshi, Shruti Chaudhary et al. Development of a cost effective “duplexed” real time PCR assay for minimal residual disease monitoring of chronic myeloid leukemia using locked nucleic acid probes. *Int J Lab Hematol*. 2016 Jul 27. doi: 10.1111/ijlh.12541. **First Author** (**Impact Factor: 3.453**)
3. **Artificial Intelligence based Prognostication of Blood Cancers:** We are one of the first research groups to demonstrate that AI can be used for genomics driven prognostication of blood cancers.
  - a. **Nikhil Patkar\***, Anam Fatima Shaikh, Chinmayee Kakirde, et al. A Novel Machine Learning Derived Genetic Score Correlates with Measurable Residual Disease and is Highly Predictive of Outcome in Acute Myeloid Leukemia with Mutated *NPM1*. *Blood Cancer Journal* 2019 ;9(10):79 (**Impact Factor: 12.8**)
  - b. Shaikh AF, Kakirde C, .., **Patkar N\*** Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1. *Leuk Lymphoma*. 2020 ;1-7 \***Corresponding Author** (**Impact Factor: 3.093**)

**Platform Presentations:**

1. Machine Learning Identifies Gene Mutations and Variant Allele Fractions that Refine the 2022 European LeukemiaNet Risk Stratification for Acute Myeloid Leukemia. **Oral Presentation** at the **66th American Society of Hematology Annual Meeting and Exposition**. San Diego, USA  
<https://ash.confex.com/ash/2024/webprogram/Paper193534.html>
2. Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing. Nikhil Patkar and colleagues. **Oral Presentation** at the **62nd American Society of Hematology Annual Meeting and Exposition**.  
<https://ash.confex.com/ash/2020/webprogram/Session19628.html>

3. Ultradeep Error Corrected Next-generation Sequencing (NGS) of ABL1 Kinase Domain Mutations in BCR-ABL1 Positive Malignancies. Nikhil Patkar and colleagues. **Oral Presentation at Annual Meeting of Association for Molecular Pathology AMP 2018**, San Antonio, Texas, USA  
<https://amp18.amp.org/program/program/cancer-oncology1/>

**Professional Memberships:**

1. Treasurer, Molecular Pathology Association of India
2. International Affairs Committee Member, Association of Molecular Pathology

**Conferred Orations:**

- a. Dr. J. G. Parekh Oration Award for 2022-23, 46th Annual Conference of Mumbai Hematology Group
- b. Dr. M.T. Paithankar Oration (Vidarbha Pathology Society) for 2023, 25<sup>th</sup> November 2023, Nagpur, Maharashtra

**Reviewer for Journals:**

1. Acta Hematologica
2. Annals of Hematology
3. BMC Cancer
4. Blood
5. British Journal of Haematology
6. Cancer Cell International
7. Cancer Genetics
8. Clinical Lymphoma, Myeloma and Leukemia
9. EClinical Medicine (Lancet)
10. Experimental Hematology & Oncology
11. Frontiers in Cell Development and Biology
12. Hematological Oncology
13. Hematology
14. Indian Journal of Cancer
15. Indian Journal of Medical Pediatric Oncology
16. Indian Journal of Haematology and Transfusion Medicine
17. Indian Journal of Orthopedics
18. Indian Journal of Medical Research
19. International Journal of Laboratory Haematology
20. Journal of Applied Microbiology
21. Journal of Molecular Diagnostics
22. Leukemia
23. Leukemia Res
24. Mediterranean Journal of Hematology and Infectious Diseases
25. Nature Communications
26. Oncology Letters
27. Scientific Reports
28. The Journal of Applied Laboratory Medicine
29. The National Medical Journal of India

**Reviewer for Grants:**

1. Indian Council of Medical Research – Small Grant, Government of India
2. Indian Council of Medical Research – Intermediate Grant, Government of India
3. Wellcome Trust DBT India Alliance, Government of India

4. Department of Biotechnology, Government of India

**International Talks:**

- a. Advances in Hematopathology and Leukemia. **Medlab Middle East Congress, 6<sup>th</sup> to 9<sup>th</sup> February 2023, Dubai**
- b. "Hematolymphoid Neoplasms" OncoPathology & 45th EAFO OncoPathology Seminar X **EAFO Basic Medical Courses: Moscow Russia.** 29 July – 12 August, 2022
  1. Evaluation of MRD in ALL
  2. Evaluation of Bone Marrow Aspirate
  3. Diagnostics in ALL
  4. Role of NGS in Myeloid Malignancies and AML
  5. Error Corrected Sequencing for MRD detection in AML.
- c. Error Corrected Sequencing to detect MRD in AML. **The International Congress of BMT 2021 S Korea (Virtual)** 26 -28 August 2021

**National Talks including CME presentations for Educational Activities (selected talks from 2018-2024):**

- a. Advances in precision oncology - Liquid Biopsy & MRD. Unlocking Precision Medicine: The Power of Comprehensive Genomic Profiling to be held in **Mumbai** on Friday, 12 April 2024 .
- b. NGS and its utility in Haematological Neoplasms. 9th Molecular Pathology Workshop April 2024 organized by **Tata Medical Center, Kolkata.** Friday, 19th April 2024
- c. Optimal Diagnostic Work Up Of AMI, Role Of NGS. Mid Term PHO CME 2024, scheduled to take place on 13th July 2024 at, **National Cancer Institute, Nagpur.**
- d. Flow Cytometry in Chronic Lymphoproliferative Disorders. 16th November,2024. **A.J. Institute of Medical Sciences and Research Centre, Mangalore**
- e. AML - Genomic landscape and genetic predisposition. 5thAnnual Conference of the Indian Society of Haematology & Blood Transfusion (ISHBT) “ **Haematocon 2024**” to be held from 07th – 10th November 2024
- f. Next Generation Sequencing in Myeloma. January 10th to 12th, 2025. **Indian Myeloma Congress 2025**
- g. Method Development in Next Generation Sequencing. February 13th to 15th, 2025. 12th Annual Conference of the Molecular Pathology Association of India (MPAICON 2025). **CMC Vellore, TN**
- h. Speaker for Selecting and investigating for an underlying germline predisposition disorder in AML/ MDS- A cased based approach. Department of Hematology at **All India Institute of Medical Sciences**, New Delhi National Hematology Update-XIII 2nd Feb 2025
- i. Two talks: Library Preparation & Basics of Panel Designing. 7th Annual Conference of the Neuropathology Society of India (NPSICON 2025), **AIIMS, New Delhi**, from 22nd February 2025.
- j. Next Generation Sequencing in Hematopathology, 18-19 April 2024,**Tata Medical Centre Kolkata**
- k. Making Genomics Accessible for Blood Cancers: TMC approach **6th Indian Cancer Genetics Conference & Workshop, 23-25 February 2024**, ACTREC, Tata Memorial Centre, Navi Mumbai.
- l. **11<sup>th</sup> Annual Conference of the Molecular Pathology Association Of India (MPAI) “ MPAICON 2024”** Genomic Landscape of AML 17 February 2024
- m. **11<sup>th</sup> Annual Conference of the Molecular Pathology Association Of India (MPAI) “ MPAICON 2024”** NGS Workshop: Library Preparation and Panel Design. 16 February 2024

- n. **11<sup>th</sup> Annual Conference of the Molecular Pathology Association Of India (MPAI) " MPAICON 2024"** Meet the Professor 18 February 2024
- o. Invited Member of DIVIA Working Group, **St Jude Global Alliance. St Jude Global Alliance Meeting** December 2-7, Memphis, Tennessee, USA
- p. **Dr. M.T. Paithankar Oration (Vidharbha Pathology Society)** for 2023, 25<sup>th</sup> November 2023, Nagpur, Maharashtra
- q. **Cytogenetics and Molecular Biology in Malignant Hematology.** Phocon 2023 24<sup>th</sup> November 2023
- r. **Role of Next Generation Sequencing in Acute Leukaemias** Cancer Institute (W.I.A.), Adyar, Chennai 24<sup>th</sup> November 2023
- s. **Workshop on NGS in Hematopathology.** 64<sup>th</sup> Conference of ISHBT Bhubaneshwar 2<sup>nd</sup>-5<sup>th</sup> November 2023. Workshop Lead Faculty
  - a. Introduction to the Workshop
  - b. Basics of Panel Design in NGS
  - c. Planning a Sequencing Experiment: Library Preparation & Sequencing
- t. **MRD assessment in AML: Data from India** Mid Term Conference of Mumbai Hematology Group. 29<sup>th</sup> September 2023
- u. **NGS in Plasma Cell Neoplasms.** XXV Indian Association of Pathologists International Division Annual CME, 9<sup>th</sup> September 2023
- v. **How do molecular tests help in getting a precise diagnosis in ALL?** ALL Practice Update, Rajiv Cancer Cancer Institute & Research Centre, New Delhi. 25<sup>th</sup> August 2023
- w. **Haematology Masterclass Conference** on 21st May 2023 at Chancery Pavilion, Bangalore, conducted by International Hematology Consortium (IHC)
- x. Represented Tata Memorial Centre in National Technology Week, Government of India, from 11-14 May 2023 on **Innovative and Cost-Effective Molecular Evaluation of Blood Cancers**, Pragati Maidan, New Delhi
- y. Max Cancer Congress 2023, Hematology update. **Genomic Evolutionary Patterns of Hematological Malignancies and its Clinical Implications.** Hotel Taj Palace, New Delhi 30th April 2023
- z. Molecular Pathology Association of India Annual Conference. **Molecular MRD Detection in Acute Myeloid Leukemia.** 16-18 February 2023. Lucknow India
- aa. Molecular Pathology Association of India Annual Conference. **Error Corrected Sequencing in Acute Myeloid Leukemia.** 6-7<sup>th</sup> August 2022. Ahmedabad India
- bb. **Molecular Diagnostic Testing in Hematologic Cancers.** CME on Molecular Pathology Approach to Cancers. 3<sup>rd</sup> December, 2021 Armed Forces Medical College, Pune
- cc. **Next Generation Sequencing.** 62<sup>nd</sup> Annual Conference of the Indian Society of Haematology & Blood Transfusion (HAEMATOCON 2021). 10th November 2021.
- dd. **Molecular techniques, pitfalls and quality issues in Acute Leukemia.** 61<sup>st</sup> Annual Conference of the Indian Society of Haematology & Blood Transfusion (HAEMATOCON 2020). 21st November 2020
- ee. **Molecular Interrogation of AML and MDS.** ISMPO Conference: Molecular Profiling Shaping the Treatment Paradigm in Hematologic Malignancies 19th Feb 2021
- ff. **Panel Discussion, Diagnosis & Monitoring of CML– Legendary Oncology Series (DALOS) |** 7th & 8th November 2020 Virtual
- gg. **Next Generation Sequencing and its Role in Hematopathology.** Annual Meeting of Karnataka Chapter of Pathology & Microbiology KAPCON 2020, 4<sup>th</sup> October 2020
- hh. **Measurable Residual Disease in Acute Myeloid Leukemia.** 26<sup>th</sup> September, 2020 Hematology Cancer Consortium, Virtual Meeting.

- ii. **Next Generation Sequencing - Applications to Myeloproliferative Neoplasms** 17th July 2020 Eastern Hematology Group, Virtual Meeting.
- jj. **Incorporating mutation testing in MDS management.** 60th Annual Conference of the Indian Society of Haematology & Blood Transfusion (HAEMATOCON 2019). 7th – 10th November 2019 in Taj Palace, New Delhi.
- kk. **How does next generation sequencing help in prognostication and monitoring of acute myeloid leukemia?** 8th Annual Conference of Molecular Pathology Association of India, MPAICON 2020 10th to 12th January 2020
- ll. **What is it and what do,I do about it?( MRD in Acute Myeloid Leukemia)**– 19th Annual International Conference “RGCON 2020” 7th February to 9th February 2020, at New Delhi, India
- mm. **Newer tools in AML for risk stratification and response assessment-NGS** Pediatric Leukemia and Lymphoma CME organized by the Division of Pediatric Hematology, Oncology and BMT, Sir Ganga Ram Hospital 8th and 9th February 2020
- nn. **Why do patients with similar cancers have different outcomes?** Explorer Series event in Chandigarh on 23 December (Monday) at IISER Mohali organized by Wellcome Trust/DBT India Alliance.
- oo. **Role of next generation sequencing in myeloid malignancies: Laboratory perspective.** 18th August, 2019 10:30 - 10:45 AM Hematology Cancer Consortium, Grand Hyatt, Kochi from 16-18 August, 2019.
- pp. **Sample Preparation and Workflow in Lab for NGS.** Best of ASCO 2019 Conference at Mumbai 28th – 30th June 2019
- qq. **Minimal Residual Disease Assessment using Ultradeep Next Generation Sequencing.** 7th Annual MPAI Conference 2019 12<sup>th</sup> -13<sup>th</sup> January 2019
- rr. **Detection of MRD in AML using Next Generation Sequencing** – 1<sup>st</sup> March 2019. Clinical Genomics in Molecular Haemato-Oncology (EBM Module, Tata Memorial Centre)
- ss. **Informatics Programs and How to Interact with them** – 28<sup>st</sup> Feb 2019. Clinical Genomics in Molecular Haemato-Oncology (EBM Module, Tata Memorial Centre)
- tt. **Sequencing - Where do we stand in routine diagnostics?** 45th Annual Conference of KCIAPM. (Karnataka State Chapter IAPM) 6<sup>th</sup> October 2018
- uu. **Theranostics in hematolymphoid neoplasms-** 45th Annual Conference of KCIAPM. (Karnataka State Chapter IAPM) 6<sup>th</sup> October 2018
- vv. **Next Generation Molecular Diagnostics in Haemato-Oncology.** 4<sup>th</sup> May 2018. Precision Medicine in Oncology NCBS, Bangalore
- ww. **Next Generation Sequencing for Haematological Malignancies.** 59th Annual Conference of The Indian Society of Haematology and Blood Transfusion. October 25th to October 28th, 2018. Grand Hyatt Kochi Bolgatty, Kerala